Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Disease Areas » Cancer » Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors

Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors

May 16, 2019
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Pediatric cancer patients with a variety of tumors harboring NTRK, ROS1, and ALK alterations saw their tumors shrink after treatment with entrectinib, an investigational drug Roche is studying in a pan-cancer indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
23
Featured Webinar

Advances in Single-Cell Proteomics: Building a Complete Picture of Cellular Identity

Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Apr
28
Featured Webinar

Spatial Multiomics: Analysis Strategies for Enriching Single-Cell Phenotyping Data: Integrative Analysis of Single-Cell Omics and Imaging Data

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

What's Popular?

In Cancer

  1. NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths

  2. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  3. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

  4. ­­­­­Intra-Tumor Heterogeneity of Dozens of Cancer Types Characterized

  5. Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.